Sumitomo Pharma Co., Ltd.
4506.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥290 | ¥161 | ¥322 | ¥480 |
| - Cash | ¥23 | ¥29 | ¥143 | ¥203 |
| + Debt | ¥305 | ¥419 | ¥346 | ¥285 |
| Enterprise Value | ¥572 | ¥551 | ¥525 | ¥561 |
| Revenue | ¥399 | ¥315 | ¥556 | ¥560 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Gross Profit | ¥245 | ¥188 | ¥377 | ¥403 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| EBITDA | ¥57 | -¥281 | -¥3 | ¥124 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |
| Net Income | ¥24 | -¥315 | -¥75 | ¥56 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| Operating Cash Flow | ¥17 | -¥242 | ¥12 | ¥31 |
| Capital Expenditures | -¥13 | -¥16 | -¥13 | -¥13 |
| Free Cash Flow | ¥3 | -¥258 | -¥1 | ¥18 |